Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
GeoVax (GOVX) Reports 2025 Year-End Financial Results and Provides Business Update
LIVE QUOTE
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Scheduled to Initiate During the Second Half of This Year
ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...
Danger Will Robinson: the NIPAH Virus with a 40-75% Death Rate Lurks.
Report: Nipah Virus Vaccine: Need, Development Landscape, and $3 Billion Market Opportunity
Report: Nipah Virus Vaccine: Need, Development Landscape, and $3 Billion Market Opportunity
Click to...
Report: AI Powered Review on GeoVax (GOVX) $1.15
In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...
Adding Cabaletta (CABA) $3.07, GeoVax (GOVX) $1.14, PolyPid (PYPD) $4.68 and Replimune (REPL) $2.17...
Biotech 12 Pack Watch List to be Released.
Biotech Stock Review is Back! Timing Feels Perfect. 4 Companies Added to Watch List.
In 2020, we Released...
Replimune (REPL). $269 Million in Cash and a $178 Million Market Cap. What are...
Adding Replimune to 2026 Watch List @ $2.17
Wife: "Honey, I'm going to the mall, do we have money in the checking?" CEO "Yes, but...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
BioPharm
David Dodd, GeoVax Labs (NASDAQ: GOVX), opines on why vaccine platform diversity is critical in the United States.
Editor's Note: The views an opinions expressed...
Happy News! GSK (GSK) Just Paid $367 Million, for Synvidia’s Pre-Clinical Trial Cancer Treatment.
One of the Fun Features of Biotech Investing, is Getting Paid on a Treatment That Hasn't Even Entered Clinical Trials.
A lot of investors...
Adding Oncolytics Biotech Inc. (ONCY) $1.02 to 2025 Watch List.
The Oncolytics Biotech Inc. (ONCY) idea is coming from one of our top 'tipsters' the Big Wig - whose two previous ideas, Allarity (ALLR)...
Latest article
Adding BCM Resources Corporation (B.V) $0.27, Up 42%, to Watch List.
'Elephant Hunter' Dr. Sergei Diakov is Expanding Drill Footprint, to Outline a Potentially Massive Copper-Gold System Beneath the Surface.
Led by legendary geologist Dr. Sergei...
New Report on Sekur Private Data (SWISF). Palantir’s Open Secure AI.
Palantir CEO Alex Karp discusses open-weight artificial intelligence models, how he believes the technology should be regulated and why the U.S. should avoid Europe’s...
Replimune (REPL) Jumps 100%.
A Nifty $415 Million Gain (in an hour) for Shareholders.
Not out of the woods yet..
Short and to the point: We listened to whole meeting...
